A decade of immune-checkpoint inhibitors in cancer therapy
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Saved in:
Main Author: | Caroline Robert |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/c42a3252354844d2a513889832446b69 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Indicators of responsiveness to immune checkpoint inhibitors
by: Bradley D. Shields, et al.
Published: (2017) -
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
by: Marka R. Crittenden, et al.
Published: (2018) -
Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
by: Katsunori Manaka, et al.
Published: (2021) -
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021) -
Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment
by: Tae Heung Kang, et al.
Published: (2020)